• Skip to main content
  • Skip to primary sidebar
  • Skip to footer
+49 (0) 69 / 606 278 – 0
[email protected]
Contact form
Patent- & Rechtsanwaltskanzlei

Patent- & Rechtsanwaltskanzlei

  • Deutsch

+49 (0) 69 / 606 278 – 0

  • Facebook
  • Twitter
  • Instagram
  • LinkedIn
  • xing
  • Email
MENUMENU
  • Services
    • Advice On Protective IP Rights
    • Patent Application /TM Registration
    • Enforcement Of IP Rights
    • Defence Against IP Rights Enforcement
    • Costs
  • Company
    • Fields of Law
      • Patent Law
      • Utility Model Law
      • Employees‘ Inventions
      • Trademark Law
      • Design Law
      • Trademark and Product Piracy
      • Expert Opinions
    • Our Law Firm
      • Dr. Karl-Hermann Meyer-Dulheuer
      • Dr. Tim Meyer-Dulheuer
      • Dr. Klaus Zimmermann
      • Zhichao Ying
      • Dr. Christoph Hölscher
    • Commitment
  • Contact
    • Where To Find Us
    • Write us!
    • Request call back
  • Blog

UK: SPC Manufacturing Waiver into force

28. June 2019

The UK Government announces that British legislation amending SPC Regulation 469/2009 will enter into force on 1 July 2019 – also known as the SPC Manufacturing Waiver. Important is that the amendment provides for an exemption from protection by an SPC.

SPC Manufacturing Waiver SPC means extension of protection

An SPC (Supplementary Protection Certificate) does not extend the term of your patent, but offers an extension of protection. It protects an authorised specific pharmaceutical or plant protection product and the use of the active substance in an authorised pharmaceutical or plant protection product during the period of validity of the SPC protected by the existing patent.

An SPC enters into force upon expiration of the patent for a period of up to 5 years. This is intended to take account of the long approval periods which are common in the pharmaceutical sector in particular and which de facto significantly shorten the 20-year term of protection of a patent.

SPC in UK granted under European law

SPCs are granted in the United Kingdom under European law under Regulation (EC) No 469/2009 of the European Parliament and of the Council for pharmaceutical products and Regulation (EC) No 1610/96 of the European Parliament and of the Council for plant protection products and related United Kingdom legislation.

The British government is now announcing that British legislation amending SPC Regulation 469/2009 will enter into force on 1 July 2019 . This is also known as the SPC Manufacturing Waiver.

Amendment of the SPC Regulation in the UK

The amendment provides for an exemption from protection by an SPC, informs the UK Government press release. The SPC Manufacturing Waiver enables manufacturers to manufacture SPC-protected medicines for export outside the EU. This would also allow the manufacture and storage of medicinal products during the last six months of an SPC ready for sale in the EU after the expiry of the SPC.

The exception initially only applies to SPCs applied for on or after 1 July 2019, as clarified in the press release. From 2 July 2022, it will also apply to SPCs applied for before 1 July 2019, but only if they did not take effect before 1 July 2019.

Prerequisites of the manufacturers

In principle, an SPC can only be applied for in the UK by those who have a valid British patent that protects the active ingredient. In addition, there must be an authorisation to place the active substance on the British market.

In order to claim the exception from protection by an SPC, manufacturers must meet certain requirements. This includes providing the SPC holder with the information required under the legislation, informs the UK Government. The manufacturer must also communicate the same information to the UK Intellectual Property Office in written paper form using the standard form. The press release states that the filing of these communications with the Office is currently free of charge.

Maybe also interesting:

  • New formulation of an active ingredient: no SPC
  • No SPC for phytase preparation – despite pharmacological effect
  • Granting of several SPCs on the basis of the same patent

 

Do you need support in patent protection for pharmaceutical or chemical products or processes?

We would be pleased to support you with the necessary research and correct registration of your trademark. Please take your chance and contact us.

Our lawyers are experienced in trademark and patent law, national and international law.


 

Sources:

Gov UK Press Release

Picture:

aloisiocostalatge /pixabay.com / CCO License

  • share  
  • share 
  • share 
  • tweet 
  • share 

Category iconHealthcare & Lifesciences,  Patent Law Tag iconPatent UK,  pharmacy,  SPC,  UK,  SPC Regulation,  SPC Manufacturing Waiver,  SPC Manufacturing Waiver into force

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

More articles about: Healthcare & Lifesciences

All articles

Blog Menu

  • Design Law
  • Healthcare & Lifesciences
  • International Intellectual Property
  • Licenses
  • News from our law firm
  • Overall
  • Patent Law
  • Product- and Trademark piracy
  • Trademark Law

Recent Posts

  • BPatG: Patent claim of cancer drug on active substance as salt 7. March 2022
  • Grant for European IP Protection: SME Fund 2022 4. March 2022
  • CODE-X vs. Cody’s: Likelihood of confusion in drinks? 25. February 2022
  • EOS lip balm no 3D trademark – appeal before ECJ not admissible 24. February 2022

Fields of Law

  • Patent Law
  • Utility Model Law
  • Employees’ Inventions
  • Trademark Law
  • Design Law
  • Trademark and Product Piracy
  • Expert Opinions
  • Costs

Das könnte Sie auch interessieren:

7. March 2022
BPatG: Patent claim of cancer drug on active substance as salt

BPatG: Patent claim of cancer drug on active substance as salt

4. March 2022
Grant for European IP Protection: SME Fund 2022

Grant for European IP Protection: SME Fund 2022

22. February 2022
PAP is in force: UPC possible in 2022

PAP is in force: UPC possible in 2022

8. February 2022
Germany: Value in dispute and costs in proceedings

Germany: Value in dispute and costs in proceedings

3. February 2022
PCT application – does the principle of joint applicants apply?

PCT application – does the principle of joint applicants apply?

1. February 2022
Proof of patent infringement by whistleblower

Proof of patent infringement by whistleblower

Contact us or request a call back

+49 (0) 69 / 606 278 – 0
[email protected]
Request a call back

Footer

Contact

Torhaus Westhafen
Speicherstrasse 59
D – 60327 Frankfurt am Main
Deutschland
+49 (0) 69 / 606 278 – 0
+49 (0) 69 / 606 278 – 199
[email protected]

Office Hours
Moday – Friday:   08:00-18:00

Fields of Law

  • Patent Law
  • Utility Model Law
  • Employees’ Inventions
  • Trademark Law
  • Design Law
  • Trademark and Product Piracy
  • Expert Opinions
  • Costs

Law Firm

  • Request non-binding call back
  • Company
  • Our Law Firm
  • ISO Certificate
  • Privacy Policy
  • Data handling for clients
  • Imprint

Follow Us

  • Facebook
  • Twitter
  • LinkedIn
  • xing
  • Email

Newsletter Signup

© Patent- & Rechtsanwaltskanzlei Meyer-Dulheuer MD Legal Patentanwälte PartG mbB

Contact Form

 

Give us a call, send us an email or fill out the contact form.

+49 (0) 69 / 606 278 – 0
[email protected]

Kontaktformular

 

Rufen Sie uns an, schicken Sie uns eine Mail oder füllen Sie das Kontaktformular aus.

+49 (0) 69 / 606 278 – 0
[email protected]